Cross-Cutting

Brain Injury

Stroke

Symposium

Genetic and biofluid based molecular biomarkers of brain injury (624141)

Presenter(s)

• 

  Maheen Adamson, PhD

  Senior Scientific Research Director/Clinical Associate Professor
  DVBIC, VA Palo Alto/Neurosurgery, Stanford School of Medicine
  Palo Alto, California
• 

  Steven Cramer, MD

  Professor, Department of Neurology
  University of California, Los Angeles
  Los Angeles, California
• EH

  E. Alison Holman, PhD, FNP

  Associate Professor
  University of California-Irvine
  Irvine, California
• LA

  Laila Abdullah, PhD

  Scientist III
  Roskamp Instiute
  Sarasota, Florida

Neuroplasticity is an important element of rehabilitation that can drive treatment planning in brain injury including stroke. It is driven by genetic and proteomic factors and incorporating both at the level of diagnosis and treatment can provide useful information at various time-points to determine focus, interventions, and progress towards overall goals and objectives. We will explore several avenues in depth in this symposium to incorporate both fluid and genetic biomarkers in diagnosis and interventions that impact rehabilitation strategies in brain injury.

Learning Objectives:

• Name three genes and their variants that have been associated differences in stroke recovery.
• determine whether using lipidomics technology can assist clinicians with an accurate diagnosis of mild TBI.
• Understand the interaction between genetic variance and myokine production during treatment for symptoms related to TBI
• Understand genetic susceptibilities to the impact of lifetime and acute stress in stroke.